Clinical markers of early nigrostriatal neurodegeneration in idiopathic rapid eye movement sleep behavior disorder

Sleep Medicine

Volumn 14, Issue 11, 2013, Pages 1064-1070

  Rupprecht, Sven ^a   Walther, Björn ^b   Gudziol, Hilmar ^a   Steenbeck, Jörg ^a   Freesmeyer, Martin ^a   Witte, Otto W ^a   Günther, Albrecht ^a   Schwab, Matthias ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Department of Neurology   (Germany)

Author keywords

Synucleinopathy; 123I FP CIT SPECT; Diagnostic accuracy; Mild motor abnormalities; Olfactory dysfunction; REM sleep behavior disorder; Transcranial sonography

Indexed keywords

IODINE 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL) N (3 FLUOROPROPYL)NOTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROIMAGING; OUTCOME ASSESSMENT; PARASOMNIA; PRIORITY JOURNAL; REM SLEEP; RISK ASSESSMENT; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING; SMELLING DISORDER; TRANSCRANIAL DOPPLER; TREATMENT DURATION;

(123)I-FP-CIT SPECT; DIAGNOSTIC ACCURACY; MILD MOTOR ABNORMALITIES; OLFACTORY DYSFUNCTION; REM SLEEP BEHAVIOR DISORDER; TRANSCRANIAL SONOGRAPHY; Α-SYNUCLEINOPATHY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CORPUS STRIATUM; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; NEURODEGENERATIVE DISEASES; OLFACTION DISORDERS; PREVALENCE; REM SLEEP BEHAVIOR DISORDER; RISK FACTORS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84886795022     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2013.06.008     Document Type: Article

References (54)

1. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
2. Boeve B.F., Silber M.H., Saper C.B., Ferman T.J., Dickson D.W., Parisi J.E., et al. Pathophysiology of REM sleep behavior disorder and relevance to neurodegenerative disease. Brain 2007, 130(pt 11):2770-2788. [published online ahead of print April 5, 2007].
3. Claassen D.O., Josephs K.A., Ahlskog J.E., Silber M.H., Tippmann-Peikert M., Boeve B.F. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010, 75:494-499. [published online ahead of print July 28, 2010].
4. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996, 46:388-393.
5. Ross G.W., Petrovitch H., Abbott R.D., Tanner C.M., Popper J., Masaki K., et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008, 63:167-173.
6. Louis E.D., Bennett D.A. Mild parkinsonian signs: an overview of an emerging concept. Mov Disord 2007, 22:1681-1688.
7. Schenck C.H., Boeve B.F., Mahowald M.W. Delayed emergence of a parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behavior disorder (RBD): 16year update on a previously reported series. Sleep Med 2013, 14:744-748. [published online ahead of print January 21, 2013].
8. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
9. Iranzo A., Molinuevo J.L., Santamaria J., Serradell M., Marti M.J., Valldeoriola F., et al. Rapid-eye-movement sleep behavior disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006, 5:572-577.
10. Tissingh G., Berendse H.W., Bergmans P., DeWaard R., Drukarch B., Stoof J.C., et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001, 16:41-46.
11. Fantini M.L., Postuma R.B., Montplaisir J., Ferini-Strambi L. Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull 2006, 70:386-390. [published online ahead of print August 6, 2007].
12. Postuma R.B., Gagnon J.F., Vendette M., Desjardins C., Montplaisir J.Y. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 2011, 69:811-818.
13. Louis E.D., Tang M.X., Schupf N. Mild parkinsonian signs are associated with increased risk of dementia in a prospective, population-based study of elders. Mov Disord 2010, 25:172-178.
14. Uemura Y., Wada-Isoe K., Nakashita S., Nakashima K. Mild parkinsonian signs in a community-dwelling elderly population sample in Japan. J Neurol Sci 2011, 304:61-66.
15. Postuma R.B., Gagnon J.F., Vendette M., Montplaisir J.Y. Markers of neurodegeneration in idiopathic rapid eye movement sleep behavior disorder and Parkinson's disease. Brain 2009, 132(Pt 12):3298-3307.
16. Booij J., Tissingh G., Boer G.J., Speelman J.D., Stoof J.C., Janssen A.G., et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:133-140.
17. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun 2005, 26:421-426.
18. Gaenslen A., Unmuth B., Godau J., Liepelt I., Di Santo A., Schweitzer K.J., et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008, 7:417-424.
19. Berg D., Becker G., Zeiler B., Tucha O., Hofmann E., Preier M., et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999, 53:1026-1031.
20. Shin H.Y., Joo E.Y., Kim S.T., Dhong H.J., Cho J.W. Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson's disease and normal control. Neurol Sci 2013, 34:935-940. [published online ahead of print July 28, 2012].
21. Stockner H., Iranzo A., Seppi K., Serradell M., Gschliesser V., Sojer M., et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009, 24:1906-1909.
22. Unger M.M., Moller J.C., Stiasny-Kolster K., Mankel K., Berg D., Walter U., et al. Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord 2008, 23:596-599.
23. Iranzo A., Valldeoriola F., Lomena F., Molinuevo J.L., Serradell M., Salamero M., et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behavior disorder: a prospective study. Lancet Neurol 2011, 10:797-805. [published online ahead of print July 28, 2011].
24. Iber C., Ancoli-Israel S., Chesson A., Quan S.F., The American Academy of Sleep Medicine The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications 2007, American Academy of Sleep Medicine, Westchester (IL). first ed.
25. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
26. APA Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington (DC). fourth ed.
27. Kobal G., Klimek L., Wolfensberger M., Gudziol H., Temmel A., Owen C.M., et al. Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds. Eur Arch Otorhinolaryngol 2000, 257:205-211.
28. Berg D., Godau J., Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008, 7:1044-1055.
29. Mozley P.D., Stubbs J.B., Kim H.J., McElgin W., Kung M.P., Meegalla S., et al. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J Nucl Med 1996, 37:151-159.
30. Dickson J.C., Tossici-Bolt L., Sera T., Erlandsson K., Varrone A., Tatsch K., et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nuc Med Mol Imaging 2010, 37:23-35.
31. 123I-N-omega-fluoropropyl-2-beta-carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes. Nucl Med Commun 2009, 30:194-201.
32. Badiavas K., Molyvda E., Iakovou I., Tsolaki M., Psarrakos K., Karatzas N. SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging 2011, 38:764-773. [published online ahead of print December 2, 2010].
33. 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004, 19:1175-1182.
34. Ottaviani S., Tinazzi M., Pasquin I., Nothdurfter W., Tomelleri G., Fincati E., et al. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. Neurol Sci 2006, 27:397-401.
35. Papathanasiou N., Rondogianni P., Chroni P., Themistocleous M., Boviatsis E., Pedeli X., et al. Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies. Ann Nucl Med 2012, 26:234-240. [published online ahead of print January 12, 2012].
36. Hosmer D.W., Lemeshow S. Applied logistic regression 2000, Wiley, New York (NY). second ed.
37. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
38. Walter U., Niehaus L., Probst T., Benecke R., Meyer B.U., Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003, 60:74-77.
39. Berg D., Merz B., Reiners K., Naumann M., Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005, 20:383-385.
40. Iranzo A., Lomena F., Stockner H., Valldeoriola F., Vilaseca I., Salamero M., et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behavior disorder: a prospective study. Lancet Neurol 2010, 9:1070-1077. [published correction appears in Lancet Neurol 2010;9:1045, published online ahead of print September 16, 2010].
41. Iwanami M., Miyamoto T., Miyamoto M., Hirata K., Takada E. Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med 2010, 11:361-365.
42. Postuma R.B., Lang A.E., Massicotte-Marquez M., Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006, 66:845-851.
43. Louis E.D., Schupf N., Marder K., Tang M.X. Functional correlates of mild parkinsonian signs in the community-dwelling elderly: poor balance and inability to ambulate independently. Mov Disord 2006, 21:411-416.
44. Postuma R.B., Lang A.E., Gagnon J.F., Pelletier A., Montplaisir J.Y. How does parkinsonism start? prodromal parkinsonism motor changes in idiopathic REM sleep behavior disorder. Brain 2012, 135(pt 6):1860-1870.
45. Stiasny-Kolster K., Doerr Y., Moller J.C., Hoffken H., Behr T.M., Oertel W.H., et al. Combination of 'idiopathic' REM sleep behavior disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005, 128:126-137.
46. Miyamoto T., Miyamoto M., Iwanami M., Hirata K., Kobayashi M., Nakamura M., et al. Olfactory dysfunction in idiopathic REM sleep behavior disorder. Sleep Med 2010, 11:458-461. [published online ahead of print April 7, 2010].
47. Doty R.L., Deems D.A., Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988, 38:1237-1244.
48. Doty R.L., Shaman P., Applebaum S.L., Giberson R., Siksorski L., Rosenberg L. Smell identification ability: changes with age. Science 1984, 226:1441-1443.
49. Miyamoto T. Olfactory dysfunction in Parkinson disease and REM sleep behavior disorder [in Japanese]. Brain Nerve 2012, 64:356-363.
50. Boesveldt S., Verbaan D., Knol D.L., Visser M., van Rooden S.M., van Hilten J.J., et al. A comparative study of odor identification and odor discrimination deficits in Parkinson's disease. Mov Disord 2008, 23:1984-1990.
51. Bohnen N.I., Gedela S., Herath P., Constantine G.M., Moore R.Y. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett 2008, 447:12-16. [published online ahead of print September 30, 2008].
52. Bohnen N.I., Gedela S., Kuwabara H., Constantine G.M., Mathis C.A., Studenski S.A., et al. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol 2007, 254:84-90. [published online ahead of print Feburary 14, 2007].
53. Kumru H., Santamaria J., Tolosa E., Iranzo A. Relation between subtype of Parkinson's disease and REM sleep behavior disorder. Sleep Med 2007, 8:779-783. [published online ahead of print September 27, 2007].
54. Ohayon M.M., Caulet M., Priest R.G. Violent behavior during sleep. J Clin Psychiatry 1997, 58:369-376. [quiz 77].